← SynDRA
ONC-206
SynDRA canonical compound SYN0040141 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | DRD2 |
|---|
| Mechanism of action | dopamine receptor antagonist |
|---|
| Indication | glioblastoma |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- dopamine receptor antagonist
- DRD2 ANTAGONIST
Cross-references
Synonyms
- ONC206
- UNII-OW6LM47PNK
- OW6LM47PNK
- 7-benzyl-4-(2,4-difluorobenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one
- SCHEMBL20464679
- NSC783746
- s6853
- NSC-783746
- HY-135147
- CS-0109614
- 4-((2,4-Difluorophenyl)methyl)-2,4,6,7,8,9-hexahydro-7-(phenylmethyl)imidazo(1,2-a)pyrido(3,4-E)pyrimidin-5(1H)-one
- 7-Benzyl-4-(2,4-difluorobenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one
- Zeltiprone
- RefChem:168241
- DRD2 Antagonist/ClpP Agonist ONC206
- zeltiprone [INN]
- orb1307929
- ONC 206 [WHO-DD]
- SCHEMBL29538852
- ONC-206, ONC206 Powder
- ONC206?
- GLXC-23355
- EX-A5759
- IUN78876
- NQC17887
- MFCD32671364
- AKOS040742338
- DA-76424
- MS-27016
- D87153
- T16392
- IUN78876; IUN-78876; IUN 78876
- Zeltiprone hydrochloride
- IT029I3UAB
Look up ONC-206 in the interactive SynDRA portal →